A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)
Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate thrice weekly dosing with vintafolide to find the maximum tolerable
dose. The primary study hypothesis is that administration of vintafolide to participants with
advanced solid tumors will have acceptable safety and tolerability.